Identification and mapping of a linear epitope of centromere protein F using monoclonal antibodies

Journal of Peptide Science

Volumn 19, Issue 2, 2013, Pages 95-101

  Welner, Simon ^a,b,c   Trier, Nicole H ^a,b,d   Houen, Gunnar ^a   Hansen, Paul ^b,d  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c LEO PHARMA A S   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Alanine substitution; CENP F; Epitope mapping; Monoclonal antibody; Resin bound peptides; Solid phase peptide synthesis

Indexed keywords

ALANINE; AUTOANTIBODY; CENTROMERE PROTEIN F; EPITOPE; MONOCLONAL ANTIBODY; NUCLEAR PROTEIN; RESIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBODY SPECIFICITY; ARTICLE; CANCER PROGNOSIS; CENTROMERE; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR RECOGNITION; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN LOCALIZATION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CHROMOSOMAL PROTEINS, NON-HISTONE; EPITOPE MAPPING; HUMANS; MICROFILAMENT PROTEINS;

EID: 84872864460     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2478     Document Type: Article

References (29)

1. Liao H, Winkfein RJ, Mack G, Rattner JB, Yen TJ. CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis. J. Cell Biology 1995; 130: 507-518.
2. Zhu XL, Mancini MA, Chang KH, Liu CY, Chen CF, Shan B, Jones D, Yangfeng TL, Lee WH. B-Characterization of a novel 350-kilodalton nuclear phosphoprotein that is specifically involved in mitotic-phase progression. Mol. Cell. Biol. 1995; 15: 5017-5029.
3. Fritzler MJ, Rattner JB, Luft LM, Edworthy SM, Casiano CA, Peebles C, Mahler M. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun. Rev. 2011; 10: 194-200.
4. Casiano CA, Humbel RL, Peebles C, Covini G, Tan EM. Autoimmunity to the cell cycle-dependent centromere protein p330d/CENP-F in disorders associated with cell proliferation. J. Autoimmunity 1995; 8: 575-586.
5. Rattner JB, Rees J, Whitehead CM, Casiano CA, Tan EM, Humbel RL, Conrad K, Fritzler MJ. High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin. Invest. Med. 1997; 20: 308-319.
6. Bencimon C, Salles G, Moreira A, Guyomard S, Coiffier B, Bienvenu J, Fabien N. Prevalence of anticentromere F protein autoantibodies in 347 patients with non-Hodgkin's lymphoma. Ann. N. Y. Acad. Sci. 2005; 1050: 319-326.
7. de la Guardia C, Casiano CA, Trinidad-Pinedo J, Baez A. CENP-F gene amplification and overexpression in head and neck squamous cell carcinomas. Head Neck 2001; 23: 104-112.
8. Shigeishi H, Mizuta K, Higashikawa K, Yoneda S, Ono S, Kamata N. Correlation of CENP-F gene expression with tumor-proliferating activity in human salivary gland tumors. Oral Oncol. 2005; 41: 716-722.
9. Hui D, Reiman T, Hanson J, Linford R, Wong W, Belch A, Lai R. Immunohistochemical detection of cdc2 is useful in predicting survival in patients with mantle cell lymphoma. Mod. Pathol. 2005; 18: 1223-1231.
10. Erlanson M, Casiano CA, Tan EM, Lindh J, Roos G, Landberg G. Immunohistochemical analysis of the proliferation associated nuclear antigen CENP-F in non-Hodgkin's lymphoma. Mod. Pathol. 1999; 12: 69-74.
11. O'Brien SL, Fagan A, Fox EJP, Millikan RC, Culhane AC, Brennan DJ, McCann AH, Hegarty S, Moyna S, Duffy MJ, Higgins DG, Landberg G, Gallagher WM. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int. J. Cancer 2007; 120: 1434-1443.
12. Koon N, Schneider-Stock R, Sarlomo-Rikala M, Lasota J, Smolkin M, Petroni G, Zaika A, Boltze C, Meyer F, Andersson L, Knuutila S, Miettinen M, El-Rifai W. Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 2004; 53: 235-240.
13. Chen WB, Cheng XB, Ding W, Wang YJ, Chen D, Wang JH, Fei RS. Centromere protein F and survivin are associated with high risk and a poor prognosis in colorectal gastrointestinal stromal tumours. J. Clinical Pat. 2011; 64: 751-755.
14. Regenmortel MHV. In Epitope Mapping Protocols, Schutkowski M, Reineke U (ed.). Humana Press: Totowa, NJ, 2009; 3-20.
15. Thomas JO, Wilson CM, Hardin JA. The major core histone antigenic determinants in systemic lupus erythematosus are in the trypsin-sensitive regions. FEBS Lett. 1984; 169:90-96.
16. Farrag L, Pendergraft WF, Yang JJ, Jennette JC, Falk RJ, Preston GA. A study of conformational restraints on reactivity of human PR3-specific autoantibodies (ANCA) facilitated through protein folding manipulations of a new recombinant proteinase 3 protein. Autoimmunity 2007; 40: 503-511.
17. Duquerroy S, Stura EA, Bressanelli S, Fabiane SM, Vaney MC, Beale D, Hamon M, Casali P, Rey FA, Sutton BJ, Taussig MJ. Crystal structure of a human autoimmune complex between IgM rheumatoid factor RF61 and IgG1 Fc reveals a novel epitope and evidence for affinity maturation. J. Mol. Biology 2007; 368: 1321-1331.
18. Smith GP, Petrenko VA. Phage display. Chem. Rev. 1997; 97: 391-410.
19. Morris GE. Epitope mapping. Methods Mol. Biol. 2005; 295: 255-268.
20. Maier RH, Maier CJ, Rid R, Hintner H, Bauer JW, Onder K. Epitope mapping of antibodies using a cell array - based polypeptide library. J. Biomol. Screening 2010; 15: 418-426.
21. Reineke U, Ivascu C, Schlief M, Landgraf C, Gericke S, Zahn G, Herzel H, Volkmer-Engergt R, Schneider-Mergener J. Identification of distinct antibody epitopes and mimotopes from a peptide array of 5520 randomly generated sequences. J. Immunol. Methods 2002; 267: 37-51.
22. Trier NH, Hansen PR, Vedeler CA, Somnier FE, Houen G. Identification of continuous epitopes of HuD antibodies related to paraneoplastic diseases/small cell lung cancer. J. Neuroimmunology, 2012; 243: 25-33.
23. Ifrah D, Doisy X, Ryge TS, Hansen PR. Structure-activity relationship study of anoplin. J. Pept. Sci. 2005; 11: 113-121.
24. Rubinstein ND, Mayrose I, Halperin D, Yekutieli D, Gershoni JM, Pupko T. Computational characterization of B-cell epitopes. Mol. Immunol. 2008; 45: 3477-3489.
25. Jackson RM. Comparison of protein-protein interactions in serine protease-inhibitor and antibody-antigen complexes: implications for the protein docking problem. Protein Sci. 1999; 8: 603-613.
26. Van Regenmortel MH. What is a B-cell epitope? Methods Mol. Biol. 2009; 524: 3-20.
27. Bogan AA, Thorn KS. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 1998; 3(280): 1-9.
28. Chen SW, Van Regenmortel MHV, Pellequer JL. Structure-activity relationships in peptide antibody complexes: implications for epitope prediction and development of synthetic peptide vaccines. Curr. Med. Chem. 2009; 16: 953-64.
29. Absolon D, Van Regenmortel MHV. Purification by immunoadsorption and immunochemical properties of histone H3. FEBS Lett. 1977; 81: 419-22.